6-K - GRFS - Equibles

UNITED STATESSECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2023

Commission File No. 001-35193

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x	Form 40-F ¨

Grifols, S.A.

TABLE OF CONTENTS

Item			Sequential Page Number
1.	Other Inside Information, dated December 29,<br>2023	d	3
Grifols, S.A.<br><br> <br><br> Avinguda de la Generalitat 152-158<br><br> 08174 Sant Cugat del Vallès<br><br> Barcelona - ESPAÑA<br><br> <br><br> Tel. [34] 935 710 500 <br><br> Fax [34] 935 710 267 <br><br> <br><br> www.grifols.com
---

Pursuant to the provisions of article 226 of the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("Grifols" or the "Company") hereby informs about the following

INSIDE INFORMATION

Following the Inside Information communication published today regarding the partial sale of Grifols' stake in Shanghai RAAS Blood Products Co., Ltd. ("SRAAS"), Grifols informs that the capital gain resulting from this transaction, compared to the acquisition price of SRAAS shares, amounts to approximately 250 million euros.

In Barcelona, on 29 December 2023

Nuria Martín Barnés
Secretary to the Board of Directors

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Grifols, S.A.
By:	/s/ David I. Bell
	Name:	David I. Bell
	Title:	Authorized Signatory

Date: December 29, 2023